Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 18, 2026

Accession no.
0001863107-26-000004
Filed
Feb 18, 2026
Trade date
Feb 15-17, 2026
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $179.3K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2026Common StockMOption exerciseAcquired+4,750––181,915Direct
Feb 15, 2026Common StockMOption exerciseAcquired+11,688––193,603Direct
Feb 15, 2026Common StockMOption exerciseAcquired+11,687––205,290Direct
Feb 15, 2026Common StockMOption exerciseAcquired+14,812––220,102Direct
Feb 17, 2026Common StockSSaleDisposed−15,459$11.60−$179,324.4204,603Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2026Common StockMOption exerciseDisposed−4,750$0.00$014,250Direct
Feb 15, 2026Common StockMOption exerciseDisposed−11,688$0.00$081,816Direct
Feb 15, 2026Common StockMOption exerciseDisposed−11,687$0.00$0128,565Direct
Feb 15, 2026Common StockMOption exerciseDisposed−14,812$0.00$0222,188Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)